Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a 24-week phase 1b, randomized, double-blind, placebo-controlled, parallel-group,
multicenter safety study comparing the tolerance profile of olesoxime (495 mg, od) when
administered on top of Interferon beta in patients with stable Relapsing Remitting Multiple
Sclerosis. Patients will be randomly allocated to olesoxime (495 mg, od) or placebo in a 1:1
ratio.